Skip to navigation Skip to content

News

Share

Institute for Clinical and Economic Review (ICER) Calls for Public Comments to Improve Value Assessment Framework

August 17, 2016

The Institute for Clinical and Economic Review (ICER) is currently conducting a review of disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis. ICER assesses the value of medications by considering price, how well a medication works compared to others, quality adjusted life years (QALYs) and other cost-effectiveness factors through a value assessment framework.

The Society submitted comments on ways to improve ICER's value assessment framework in response to ICER's open call.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.

Share